

Comparison of doxycycline alone versus doxycycline plus rifampicin in their efficacy against lymphatic filariasis

Submission date 19/03/2009	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 30/04/2009	Overall study status Completed	☐ Protocol
Last Edited 20/11/2012	Condition category Infections and Infestations	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Achim Hoerauf, Director, MD

Contact details

Institute of Medical Microbiology, Immunology and Parasitology

University of Bonn, Faculty of Medicine

Sigmund Freud Str.25

Bonn

Germany

53105

+49 (0)228 287 15675

hoerauf@microbiology-bonn.de

Additional identifiers

Protocol serial number

Grant number: 39284

Study information

Scientific Title

Comparison of doxycycline alone versus doxycycline plus rifampicin in their efficacy against lymphatic filariasis: a randomised, double-blind, placebo-controlled trial

Acronym

A-WOL LF

Study objectives

1. To refine existing regimes of drugs with known activity against Wolbachia (doxycycline, rifampicin):

1.1. To provide a shortened treatment period compared to the "gold-standard" (200 mg doxycycline per day for 4 weeks) using the combination of doxycycline and rifampicin

1.2. To provide a reduction of the daily dosage of doxycycline from 200 mg to 100 mg

2. To verify an ameliorating effect of doxycycline and the combination of doxycycline and rifampicin on the dilation of supratesticular lymphatic vessels (i.e. subclinical lymphatic pathology) using the different drug regimes

As of 01/12/2009 an additional follow-up timepoint after 18 months was approved by all three ethics committees for the secondary outcomes. Please see the secondary outcome measures section below for more details.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical clearances have been obtained from the Committee on Human Research Publication and Ethics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana (approved 16th April 2008), from the Ethical Committee, University Clinic Bonn, Faculty of Medicine, Bonn, Germany (approved 18th March 2008) and from the Research Ethics Committee, Liverpool School of Tropical Medicine, Liverpool, UK (approved 26th March 2008).

Study design

Randomised double-blind placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lymphatic filariasis (*Wuchereria bancrofti*)

Interventions

The participants are randomised and assigned to one of the following seven treatment regimens:

Treatment regimen 1 (n = 65):

4 weeks doxycycline 200 mg followed by 1 week placebo matching doxycycline (2 capsules/day)

3 weeks placebo matching rifampicin (3 or 4 capsules)

Treatment regimen 2 (n = 39):

5 weeks doxycycline 100 mg (1 capsule/day)

5 weeks placebo matching doxycycline (1 capsule/day)

3 weeks placebo matching rifampicin (3 or 4 capsules)

Treatment regimen 3 (n = 39):

4 weeks doxycycline 100 mg followed by 1 week placebo matching doxycycline (1 capsule/day)

5 weeks placebo matching doxycycline (1 capsule/day)

3 weeks placebo matching rifampicin (3 or 4 capsules)

Treatment regimen 4 (n = 39):

3 weeks doxycycline 200 mg followed by 2 weeks placebo matching doxycycline (2 capsules/day)

3 weeks rifampicin (10 mg/kg BW, 3 or 4 capsules at 150 mg/day)

Treatment regimen 5 (n = 39):

2 weeks doxycycline 200 mg followed by 3 weeks placebo matching doxycycline (2 capsules/day)

2 weeks rifampicin (10 mg/kg BW) followed by 1 week placebo matching rifampicin (3 or 4 capsules/day)

Treatment regimen 6 (n = 39):

10 days doxycycline 200 mg followed by 25 days placebo matching doxycycline (2 capsules/day)

10 days rifampicin (10 mg/kg BW) followed by 11 days placebo matching rifampicin (3 or 4 capsules/day)

Treatment regimen 7 (n = 39):

5 weeks placebo matching doxycycline (2 capsules/day)

3 weeks placebo matching rifampicin (3 or 4 capsules/day)

The total duration of follow-up for all arms of our trial is 24 months after the start of drug administration.

Contact details for Joint Principal Investigators:

Prof Dr Ohene Adjei

Kwame Nkrumah University of Science and Technology (KNUST), and Kumasi Centre of Collaborative Research (KCCR)

University Post Office

Kumasi, Ghana

Tel: + 233 51 60351

Fax: + 233 51 62017

E-mail: oadjei@africaonline.com

Dr Alexander Yaw Debrah

Kwame Nkrumah University of Science and Technology (KNUST), and Kumasi Centre of Collaborative Research (KCCR)

University Post Office

Kumasi, Ghana

Tel: + 233 51 60351

Fax: + 233 51 62017

E-mail: yadebrah@yahoo.com

Intervention Type

Drug

Phase

Drug/device/biological/vaccine name(s)

Doxycycline, rifampicin

Primary outcome(s)

Current primary outcome measures as of 08/11/2012 (protocol change approved by the DMEC of this trial on 02/03/2011, before de-blinding on 24/05/2011):

Macrofilaricidal effect of the different treatment arms verified as absence of worm nests (Filaria Dance sign [FDS]; adult filariae in dilated lymphatic vessels) in the suprastesticular vessels detected by ultrasonography, assessed 12 months after the start of drug administration.

Previous primary outcome measures until 08/11/2012:

Macrofilaricidal effect of the different treatment arms assessed by reduction in the number of worm nests (Filaria Dance sign [FDS]; adult filariae in dilated lymphatic vessels) in the suprastesticular vessels detected by ultrasonography, measured pre-treatment as well as 12 months after the start of drug administration.

For all above mentioned primary and secondary outcome measures: Treatment regimens 2 to 6 will subsequently be tested first for superiority compared to placebo (regimen 7) and second for equivalence to the standard therapy (regimen 1).

Key secondary outcome(s)

Current secondary outcome measures as of 08/11/2012 (protocol change approved by the DMEC of this trial on 02/03/2011, before de-blinding on 24/05/2011):

1. Macrofilaricidal effect of the different treatment arms verified as absence of FDS in the suprastesticular vessels detected by ultrasonography, assessed 18 and 24 months after the start of drug administration
2. Macrofilaricidal effect of the different treatment arms assessed by reduction in the number of FDS in the suprastesticular vessels detected by ultrasonography compared to pre-treatment, determined 12, 18 and 24 months after the start of drug administration
3. Macrofilaricidal effect of the different treatment arms assessed by reduction of circulating filarial antigen (CFA) levels compared to pre-treatment, measured by TropBio® ELISA and ICT card test 12, 18 and 24 months after the start of drug administration
4. Long-term sterilising effect of the female adult worms in the different treatment arms as assessed by microfilaria (mf) count (filtration method):
 - 4.1 Reduction (%) or absence of microfilariae
 - 4.2 Duration (months) of amicrofilaraemia
5. Reduction (%) or absence of Wolbachia ftsZ copy numbers/microfilariae compared to pre-treatment, assessed by polymerase chain reaction (PCR) 4, 12, 18 and 24 months after the start of drug administration
6. Reduction of suprastesticular lymphatic vessel dilation compared to pre-treatment, measured 12, 18 and 24 months after the start of drug administration
7. Parasite specific immuno-globulin subclasses and cytokine responses, as well as other biomarkers such as vascular endothelial growth factors (VEGFs) measured pre-treatment as well as 4, 12 and 24 months after the start of drug administration

Previous secondary outcome measures as of 01/12/2009, until 08/11/2012:

1. Macrofilaricidal effect of the different treatment arms assessed by reduction in the number of worm nests in the suprastesticular vessels detected by ultrasonography, measured 18 and 24 months after the start of drug administration

2. Macrofilaricidal effect of the different treatment arms assessed by absence of FDS in the suprastesticular vessels detected by ultrasonography, measured pre-treatment as well as 12, 18 and 24 months after the start of drug administration
3. Macrofilaricidal effect of the different treatment arms assessed by levels of antigenaemia (enzyme-linked immunosorbent assay [ELISA] test) - reduction of circulating filarial antigen [CFA]) - measured pre-treatment as well as 4, 12, 18 and 24 months after the start of drug administration
4. Long-term sterilising effect of the female adult worms in the different treatment arms as assessed by microfilaria (mf) count (filtration method) and polymerase chain reaction (PCR) analysis:
 - 4.1. Reduction (%) or absence of microfilariae
 - 4.2. Duration (months) of amicrofilaraemia
 - 4.3. Reduction (%) or absence of Wolbachia ftsZ copy numbers/microfilariae assessed by PCR Measured pre-treatment as well as 4, 12, 18 and 24 months after the start of drug administration
5. Reduction of suprastesticular lymphatic vessel dilation measured pre-treatment as well as 12, 18 and 24 months after the start of drug administration
6. Parasite specific immuno-globulin subclasses and cytokine responses, as well as other biomarkers such as vascular endothelial growth factors (VEGFs) measured pre-treatment as well as 4, 12, 18 and 24 months after the start of drug administration

For all above mentioned primary and secondary outcome measures: Treatment regimens 2 to 6 will subsequently be tested first for superiority compared to placebo (regimen 7) and second for equivalence to the standard therapy (regimen 1).

Initial information at time of registration:

1. Macrofilaricidal effect of the different treatment arms assessed by reduction in the number of worm nests in the suprastesticular vessels detected by ultrasonography, measured 24 months after the start of drug administration
2. Macrofilaricidal effect of the different treatment arms assessed by absence of FDS in the suprastesticular vessels detected by ultrasonography, measured pre-treatment as well as 12 and 24 months after the start of drug administration
3. Macrofilaricidal effect of the different treatment arms assessed by levels of antigenaemia (enzyme-linked immunosorbent assay [ELISA] test) - reduction of circulating filarial antigen [CFA]) - measured pre-treatment as well as 4, 12 and 24 months after the start of drug administration
4. Long-term sterilising effect of the female adult worms in the different treatment arms as assessed by microfilaria (mf) count (filtration method) and polymerase chain reaction (PCR) analysis:
 - 4.1. Reduction (%) or absence of microfilariae
 - 4.2. Duration (months) of amicrofilaraemia
 - 4.3. Reduction (%) or absence of Wolbachia ftsZ copy numbers/microfilariae assessed by PCR Measured pre-treatment as well as 4, 12 and 24 months after the start of drug administration
5. Reduction of suprastesticular lymphatic vessel dilation measured pre-treatment as well as 12 and 24 months after the start of drug administration
6. Parasite specific immuno-globulin subclasses and cytokine responses, as well as other biomarkers such as vascular endothelial growth factors (VEGFs) measured pre-treatment as well as 4, 12 and 24 months after the start of drug administration

For all above mentioned primary and secondary outcome measures: Treatment regimens 2 to 6 will subsequently be tested first for superiority compared to placebo (regimen 7) and second for equivalence to the standard therapy (regimen 1).

Completion date

30/04/2011

Eligibility

Key inclusion criteria

Current inclusion criteria as of 08/11/2012 (protocol change approved by the DMEC of this trial on 02/03/2011):

1. Men aged between 18 - 50 years
2. Good general health without any clinical condition requiring long-term medication and with normal renal and hepatic laboratory profiles
3. Body weight (BW): ≥ 40 kg
4. Presence of at least one scrotal worm nest detected by ultrasonography

Previous inclusion criteria until 08/11/2012:

3. Body weight (BW): 40 - 70 kg

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Male

Key exclusion criteria

1. Known intolerance to the study drugs (doxycycline, rifampicin), or to ivermectin and/or albendazole
2. History of severe allergic reaction or anaphylaxis
3. History of alcohol or drug abuse
4. Anti-filarial therapy within the last 10 months
5. Evidence of clinically significant neurological, cardiac, pulmonary, hepatic, metabolic, rheumatologic or renal disease as far as it can be assessed by history of participants, physical examination, and/or laboratory examinations including blood and urine analysis
6. Laboratory evidence of liver disease (alanine aminotransferase [ALT], gamma-glutamyl transferase [gamma-GT] greater than 1.25 times the upper limit of normal results as stated by the manufacturer of dipstick tests, Roche®)
7. Laboratory evidence of renal disease (serum creatinine greater than 1.25 times the upper limit of normal results as stated by the manufacturer of dipstick tests, Roche®)
8. Laboratory evidence of diabetes (urine dipstick chemistry)
9. Behavioural, cognitive or psychiatric disease that in the opinion of the trial clinician affects the ability of the participant to understand and comply with the study
10. Severe asthma or respiratory disease (emergency room visit or hospitalisation)

11. Undergone splenectomy
12. Participation in other drug trials concurrent with this study
13. Any other condition that, in the opinion of the investigator (trial clinician), would risk the safety or rights of a participant in the trial or would render the subject unable to comply with the protocol

Date of first enrolment

01/05/2008

Date of final enrolment

30/04/2011

Locations

Countries of recruitment

Germany

Ghana

Study participating centre

Institute of Medical Microbiology, Immunology and Parasitology

Bonn

Germany

53105

Sponsor information

Organisation

Liverpool School of Tropical Medicine (UK)

ROR

<https://ror.org/03svjbs84>

Funder(s)

Funder type

Research organisation

Funder Name

Bill and Melinda Gates Foundation (USA) - via the Liverpool School of Tropical Medicine (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes